title: Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation.
abstract: IL-5 is a prominent and perhaps an essential element in the induction of allergic inflammation in human asthma and other allergic diseases. Despite the strong biochemical and clinical correlates between lung eosinophilia and asthma, there is no clear understanding of how eosinophils exacerbate asthma. Antigen administration to sensitized animals produces eosinophilic infiltration that is very similar to that in man, and is prevented by administration of a neutralizing monoclonal antibody against IL-5. Mice in which the IL-5 gene is absent are unable to mount eosinophilic responses to antigen and do not sustain lung damage, but otherwise develop normally. The study of the biology of IL-5 has not only clarified the links between eosinophilia and airway hyperreactivity, but also strongly suggests that anti-IL-5 therapy may be an effective, safe, and novel way of treating human asthma and perhaps other eosinophilic diseases. There are many different potential approaches to the inhibition of IL-5, but the one most likely to provide "proof of principle" in "asthma in the wild" in man is a monoclonal antibody against IL-5.
authors.affiliation: Department of Clinical Research, Schering-Plough Research Institute, Kenilworth, NJ, USA.
authors.forename: M
authors.initials: M
authors.lastname: Danzig
authors.forename: F
authors.initials: F
authors.lastname: Cuss
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000628:therapy; D003876:Dermatitis, Atopic / Q000628:therapy; D004804:Eosinophils / Q000276:immunology / Q000378:metabolism; D006168:Guinea Pigs; D000882:Haplorhini; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology* / Q000628:therapy*; D015848:Interleukin-5 / Q000037:antagonists & inhibitors*; D051379:Mice; D018345:Mice, Knockout; D009298:Nasal Polyps / Q000628:therapy; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology / Q000628:therapy
chemical_list: D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D015848:Interleukin-5